bamlanivimab - International Biopharmaceutical Industry

Current Edition

Issue 9, Volume 3

Current Features

Issue 9, Volume 3

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

news

Lilly drug becomes first COVID antibody cleared for use in young children

When bamlanivimab gained initial authorization 13 months ago, it was the first drug specifically designed to arrest infections of the SARS-CoV-2 virus that causes COV...

10 December 2021 news bamlanivimab | COVID

Continue Reading →

news

US stocks up on COVID-19 antibody drugs amid shortage concerns

The antibody treatments from Regeneron and Eli Lilly have been proven effective in reducing the risk of hospitalization or death from COVID-19 in certain high-risk in...

17 September 2021 news Antibody | bamlanivimab

Continue Reading →